ebola
viru
ebov
infect
caus
sever
frequent
fatal
diseas
human
patient
ebov
glycoprotein
gp
mediat
viral
entri
host
cell
gp
depend
prime
phdepend
endolysosom
cystein
proteas
cathepsin
b
catb
lesser
degre
cathepsin
l
catl
least
cell
cultur
system
howev
limit
inform
whether
ebovgp
acquir
resist
catbl
inhibitor
address
question
use
replicationcompet
vesicular
stomat
viru
bear
ebovgp
five
passag
viru
presenc
catbcatl
inhibitor
suffici
select
resist
viral
variant
sequenc
reveal
gp
sequenc
contain
mutat
context
nativ
gp
locat
base
gp
surfac
unit
addit
gp
sequenc
harbor
mutat
receptorbind
domain
final
mutat
analysi
demonstr
confer
resist
catbcatl
inhibitor
collect
singl
amino
acid
substitut
gp
suffici
confer
resist
catbcatl
inhibitor
suggest
usag
catbcatl
inhibitor
antivir
therapi
may
rapidli
select
resist
viral
variant
envelop
limit
membran
endolysosom
allow
deliveri
viral
genom
host
cell
cytoplasm
bind
membran
fusion
carri
differ
subunit
gp
ntermin
surfac
unit
bind
host
cell
receptor
via
receptorbind
domain
rbd
ctermin
transmembran
unit
harbor
function
element
requir
membran
fusion
includ
fusion
peptid
heptad
repeat
although
bind
attach
factor
cell
surfac
interact
intracellular
receptor
niemannpick
within
host
cell
endolysosom
essenti
ebov
entri
interact
critic
depend
previou
process
ebovgp
endolysosom
phdepend
cystein
proteas
cathepsin
b
catb
cathepsin
l
catl
process
remov
glycan
cap
mucinlik
domain
mld
result
prime
form
gp
prime
gp
still
contain
rbd
link
via
disulfid
bond
fuse
viral
membran
endolysosom
membran
upon
receipt
trigger
howev
natur
trigger
remain
identifi
light
import
role
catbcatl
ebovgpdriven
entri
inhibitor
target
enzym
might
hold
therapeut
potenti
although
state
catbcatl
depend
vari
filovirus
target
cell
type
observ
experiment
infect
mice
previou
studi
employ
replicationcompet
vsv
chimera
bear
ebovgp
without
mld
vsvebov
examin
resist
develop
catb
inhibitor
resist
develop
observ
two
passag
due
acquisit
singl
amino
acid
substitut
interfac
increas
suscept
mutant
gp
process
host
cell
proteas
contrast
resist
develop
context
fulllength
ebovgp
catbcatl
inhibitor
examin
show
passag
vsvebov
presenc
catbcatl
inhibitor
result
rapid
acquisit
singl
amino
acid
exchang
confer
resist
catbcatl
inhibitor
author
contribut
conceptu
mh
sp
formal
analysi
mh
investig
mh
svk
cf
wm
asm
methodolog
mh
supervis
mh
sp
writingorigin
draft
mh
sp
writingreview
edit
mh
sp
ebola
viru
ebov
member
famili
filovirida
envelop
singlestrand
rna
viru
caus
sever
frequent
fatal
diseas
ebola
viru
diseas
evd
human
west
african
evd
epidem
ongo
evd
outbreak
democrat
republ
congo
demonstr
ebov
pose
sever
threat
human
health
threat
compound
recent
find
demonstr
ebov
persist
convalesc
patient
relaps
even
month
recov
evd
may
transmit
viru
other
present
neither
vaccin
therapeut
approv
regulatori
agenc
use
human
although
clinic
trial
indic
vaccin
base
replicationcompet
vesicular
stomat
viru
vsv
bear
ebov
glycoprotein
gp
effici
protect
evd
therefor
new
antivir
strategi
need
establish
first
step
viral
replic
cycl
viral
entri
target
cell
attract
target
viral
gp
incorpor
viral
envelop
mediat
bind
ebov
target
cell
mainli
macrophag
dendrit
cell
moreov
gp
facilit
fusion
viral
order
studi
resist
develop
catbcatl
inhibitor
use
vsvebov
chimer
viru
encod
firefli
luciferas
egfp
figur
examin
inhibit
catb
andor
catl
inhibitor
catl
inhibitor
iii
larg
specif
catb
catl
inhibitor
iii
inhibit
catb
catl
vero
cell
chosen
experiment
sinc
cell
line
allow
effici
replic
ebov
previous
use
studi
inhibit
ebovgpdriven
entri
catbcatl
inhibitor
develop
viral
resist
inhibitor
preincub
vero
cell
inhibitor
follow
infect
vsvebov
univers
result
effici
dosedepend
inhibit
infect
valu
catl
inhibitor
iii
figur
moreov
catl
inhibitor
iii
reduc
vsvebov
infect
background
level
appli
without
elicit
unwant
cytotox
figur
c
contrast
reduc
vsvebov
infect
caus
measur
cytotox
effect
although
state
vsv
infect
affect
concentr
figur
c
lack
unspecif
vsv
inhibit
despit
measur
cytotox
might
result
differ
incub
period
infect
effici
measur
h
addit
compound
cytotox
measur
h
addit
compound
sum
defin
experiment
condit
ebovgpbut
vsvgdriven
entri
block
catbcatl
inhibitor
concentrationdepend
manner
select
analysi
compound
caus
dosedepend
inhibit
vsvebov
broader
rang
concentr
catl
inhibitor
iii
nonspecif
sideeffect
cell
viabil
infect
vsv
concentr
order
determin
ebovgp
acquir
resist
experiment
setup
depict
figur
chosen
first
vsvebov
passag
time
vero
cell
presenc
concentr
reduc
vsvebov
infect
without
caus
unwant
cytotox
effect
sensit
passag
control
viru
analyz
gp
sequenc
determin
figur
purpl
catl
inhibitor
iii
orang
dmso
control
cell
viabil
quantifi
present
combin
data
three
independ
experi
viabil
controltr
cell
set
error
bar
indic
sem
statist
signific
differ
cell
viabil
controland
inhibitortr
cell
analyz
oneway
analysi
varianc
dunnett
posttest
p
signific
indic
p
p
p
select
analysi
compound
caus
dosedepend
inhibit
vsvebov
broader
rang
concentr
catl
inhibitor
iii
nonspecif
sideeffect
cell
viabil
infect
vsv
concentr
order
determin
ebovgp
acquir
resist
experiment
setup
depict
figur
chosen
first
vsvebov
passag
time
vero
cell
presenc
concentr
reduc
vsvebov
infect
without
caus
unwant
cytotox
effect
sensit
passag
control
viru
analyz
gp
sequenc
determin
figur
absenc
control
viru
passag
passag
viru
replic
compar
kinet
controltr
cell
figur
contrast
passag
viru
replic
effici
presenc
compar
wt
viru
figur
indic
passag
associ
resist
like
due
acquisit
mutat
inde
sequenc
reveal
passag
invari
associ
emerg
amino
acid
substitut
case
also
figur
c
absenc
control
viru
passag
passag
viru
replic
compar
kinet
controltr
cell
figur
contrast
passag
viru
replic
effici
presenc
compar
wt
viru
figur
indic
passag
associ
resist
like
due
acquisit
mutat
inde
sequenc
reveal
passag
invari
associ
emerg
amino
acid
substitut
case
also
figur
c
introduct
ebovgp
interfer
robust
gp
express
transfect
cell
figur
incorpor
vsv
particl
figur
moreov
mutat
alter
ebovgpdriven
entri
cell
line
fruit
bat
natur
reservoir
macaqu
anim
model
african
green
monkey
anim
model
vero
human
accident
host
origin
figur
addit
subunit
contain
intern
fusion
loop
ifl
green
two
heptad
repeat
domain
light
brown
dark
brown
transmembran
domain
tmd
dark
grey
highlight
scheme
region
ebovgp
amino
acid
substitut
detect
within
studi
amino
acid
sequenc
ebovgp
vsvebov
shown
first
row
follow
correspond
sequenc
obtain
five
passag
untreat
inhibitor
control
cathepsin
inhibitortr
vero
cell
dot
indic
ident
amino
acid
residu
compar
letter
b
c
refer
independ
experi
c
chronolog
occurr
mutat
passag
row
rectangl
ac
repres
independ
experi
blue
red
color
highlight
wildtyp
mutant
amino
acid
residu
rectangl
split
color
indic
passag
mix
popul
introduct
ebovgp
interfer
robust
gp
express
transfect
cell
figur
incorpor
vsv
particl
figur
moreov
highlight
scheme
region
ebovgp
amino
acid
substitut
detect
within
studi
amino
acid
sequenc
ebovgp
vsvebov
shown
first
row
follow
correspond
sequenc
obtain
five
passag
untreat
inhibitor
control
cathepsin
inhibitortr
vero
cell
dot
indic
ident
amino
acid
residu
compar
letter
b
c
refer
independ
experi
c
chronolog
occurr
mutat
passag
row
rectangl
ac
repres
independ
experi
blue
red
color
highlight
wildtyp
mutant
amino
acid
residu
rectangl
split
color
indic
passag
mix
popul
confer
resist
catl
inhibitor
iii
fail
confer
enhanc
resist
test
alon
combin
respect
figur
thu
singl
amino
acid
mutat
rapidli
aris
upon
passag
vsvebov
presenc
confer
resist
relat
inhibitor
confer
resist
catl
inhibitor
iii
fail
confer
enhanc
resist
test
alon
combin
respect
figur
thu
singl
amino
acid
mutat
rapidli
aris
upon
passag
vsvebov
presenc
confer
resist
relat
inhibitor
multipl
compound
shown
interfer
differ
step
ebov
lifecycl
includ
inhibitor
cellular
cystein
proteas
howev
none
compound
approv
regulatori
agenc
treatment
evd
reason
lack
approv
antivir
drug
includ
unknown
antivir
efficaci
vivo
data
stem
vitro
experiment
ii
potenti
unwant
sideeffect
patient
iii
potenti
resistancedevelop
viru
treatment
therefor
promis
compound
new
multipl
compound
shown
interfer
differ
step
ebov
lifecycl
includ
inhibitor
cellular
cystein
proteas
howev
none
compound
approv
regulatori
agenc
treatment
evd
reason
lack
approv
antivir
drug
includ
unknown
antivir
efficaci
vivo
data
stem
vitro
experiment
ii
potenti
unwant
sideeffect
patient
iii
potenti
resistancedevelop
viru
treatment
therefor
promis
compound
new
target
intervent
character
regard
aforement
point
order
identifi
new
option
treatment
evd
previou
studi
wong
colleagu
demonstr
passag
vsvebov
lack
mld
presenc
catb
inhibitor
rapidli
select
mutat
confer
resist
ie
allow
effici
infect
target
cell
presenc
inhibitor
mutat
select
result
amino
acid
substitut
posit
nterminu
ebovgp
context
properli
fold
matur
protein
region
contain
amino
acid
residu
locat
base
interact
moreov
amino
acid
substitut
increas
effici
proteolyt
process
precleav
gp
render
particl
bear
precleav
gp
suscept
inactiv
proteolyt
digest
consequ
propos
mutat
confer
resist
catb
inhibitor
destabil
gp
trimer
therebi
render
access
proteolyt
digest
catbcatl
increas
effici
gp
trigger
addit
postul
mutat
render
gpdriven
entri
catbindepend
allow
gp
process
far
unidentifi
endosom
cystein
proteas
catb
present
studi
confirm
extend
find
report
wong
cowork
show
also
context
fulllength
ebovgp
singl
amino
acid
substitut
locat
within
base
rapidli
acquir
upon
passag
viru
presenc
inhibitor
suffici
confer
resist
light
almost
ident
locat
resist
mutat
compar
one
describ
like
confer
resist
via
similar
mechan
moreov
demonstr
resist
develop
occur
presenc
inhibitor
unlik
catbspecif
compound
use
previou
studi
block
catb
catl
activ
context
mention
confer
complet
resist
larg
catbspecif
inhibitor
highest
concentr
test
catbcatlspecif
inhibitor
catl
inhibitor
iii
suggest
mutat
might
render
entri
catb
catl
independ
thu
mutat
might
induc
chang
ebovgp
structur
render
catb
cleavag
site
also
access
catl
relat
cystein
proteas
suscept
inhibit
catl
inhibitor
iii
altern
might
destabil
gp
way
incomplet
process
gp
catl
andor
proteas
might
suffici
render
gp
suscept
membran
fusion
trigger
inhibitor
block
catb
andor
catl
activ
entri
ebov
emerg
coronavirus
nipah
viru
also
reli
cystein
cathepsin
glycoprotein
process
describ
moreov
shown
block
coronaviru
spread
pathogenesi
rodent
model
whether
also
block
ebov
spread
host
whether
result
rapid
emerg
resist
virus
suggest
present
studi
remain
determin
final
interest
investig
whether
resist
come
costfor
instanc
increas
sensit
toward
antibodymedi
neutral
andor
augment
sensit
toward
blockad
interferoninduc
antivir
effector
protein
human
embryon
kidney
atcc
vero
african
green
monkey
kidney
atcc
rhesu
macaqu
kidney
atcc
buettikof
epaulet
fruit
bat
kidney
kindli
provid
c
drosten
cell
line
obtain
collabor
cell
grown
dulbecco
modifi
eagl
medium
dmem
pan
biotech
supplement
fetal
bovin
serum
fb
pan
biotech
well
penicillin
streptomycin
stock
solut
pan
biotech
cell
line
cultiv
c
co
humidifi
atmospher
transfect
cell
achiev
calcium
phosphat
precipit
recombin
vsv
employ
code
dual
report
consist
enhanc
green
fluoresc
protein
egfp
firefli
luciferas
fluc
dual
report
express
addit
express
cassett
insert
open
read
frame
vsvg
vsvl
chimer
vsv
use
contain
genet
inform
ebovgp
mayinga
variant
genbank
instead
vsv
glycoprotein
vsvg
thu
lead
product
vsv
harbor
ebovgp
sole
viral
surfac
glycoprotein
vsvebov
figur
virus
propag
titrat
vero
cell
util
previous
describ
pcaggsbas
express
plasmid
ebovgp
wt
variant
lack
mucinlik
domain
amino
acid
residu
vsvg
empti
pcagg
vector
serv
neg
control
express
plasmid
mutant
ebovgp
harbor
amino
acid
substitut
construct
overlap
extens
pcr
use
plasmid
ebovgp
wt
templat
sequenc
ident
confirm
autom
sequenc
analysi
microsynth
seqlab
order
block
activ
catb
andor
catl
follow
inhibitor
use
calpain
inhibitor
also
inhibit
catbl
sigmaaldrich
specif
catb
inhibitor
merck
cat
l
inhibitor
iii
catl
inhibitor
also
activ
catb
merck
inhibitor
reconstitut
dimethyl
sulfoxid
dmso
prepar
stock
solut
mm
concentr
target
cell
treat
inhibitor
h
infectiontransduct
cell
treat
dmso
instead
inhibitor
serv
control
order
ensur
longlast
catbl
inhibit
vitroevolut
experi
medium
ad
cell
wash
away
viral
inoculum
also
supplement
inhibitor
dmso
control
identif
optim
inhibitor
concentr
subsequ
vitroevolut
experi
target
cell
pretreat
dmso
control
increas
concentr
inhibitor
inocul
either
vsv
vsvebov
use
multipl
infect
moi
case
vitroevolut
experi
vsvebov
use
moi
infect
cell
cultur
supernat
contain
dmsoinhibitor
remov
cell
inocul
viru
h
c
co
afterward
inoculum
remov
cell
wash
pb
medium
contain
fresh
dmsoinhibitor
ad
case
experi
address
optim
inhibitor
concentr
infect
stop
h
postinfect
vitroevolut
experi
supernat
harvest
cell
posit
egfp
express
judg
fluoresc
microscopi
typic
achiev
h
harvest
supernat
freed
cellular
debri
centrifug
aliquot
store
c
consecut
inocul
fresh
target
cell
aliquot
respect
previou
passag
thaw
dilut
inocul
identifi
optim
inhibitor
concentr
subsequ
vitroevolut
experi
replic
vsv
vsvebov
analyz
measur
fluc
activ
cell
lysat
h
postinfect
use
beetl
juic
kit
pjk
plate
luminomet
hidex
normal
infect
effici
indic
fluc
activ
dmsotreat
cell
set
rel
infect
effici
cell
pretreat
increas
concentr
inhibitor
calcul
accordingli
order
compar
viral
growth
kinet
unpassag
vsvebov
vsvebov
passag
inhibitortr
cell
viral
titer
determin
calcul
tissu
cultur
infecti
dose
per
ml
describ
employ
rhabdovir
transduct
vector
base
replicationdefici
vsv
code
egfp
fluc
instead
vsvg
kindli
provid
g
zimmer
pseudotyp
vector
wt
mutant
ebovgp
vsvg
posit
control
perform
accord
publish
protocol
empti
particl
produc
absenc
viral
glycoprotein
serv
neg
control
transduct
target
cell
inocul
equal
volum
supernat
contain
pseudotyp
vsv
h
posttransduct
effici
transduct
quantifi
measur
fluc
activ
cell
lysat
accord
publish
protocol
total
express
wt
mutant
ebovgp
well
particl
incorpor
investig
sdspage
sodium
polyacrylamid
gel
electrophoresi
western
blot
analysi
whole
cell
lysat
wcl
cell
express
wt
mutant
gp
gp
neg
control
prepar
follow
h
posttransfect
cultur
supernat
remov
cell
wash
pb
mix
sd
sampl
buffer
trishcl
glycerol
sd
bromophenol
blue
betamercaptoethanol
mm
edta
cell
lysi
min
incub
room
temperatur
sampl
heat
c
addit
min
analyz
ebovgp
particl
incorpor
rhabdovir
transduct
vector
concentr
via
centrifug
sucros
cushion
g
h
c
mix
sd
sampl
buffer
incub
describ
sdspage
protein
blot
onto
nitrocellulos
membran
hartenstein
gmbh
block
incub
pbst
pb
contain
tween
skim
milk
powder
min
room
temperatur
incub
primari
antibodi
dilut
pbst
perform
overnight
c
detect
ebovgp
use
serum
rabbit
detect
load
control
betaactin
actb
wcl
vsv
matrix
protein
vsvm
particl
incorpor
antiactb
mous
sigmaaldrich
antivsvm
antibodi
mous
kerafast
use
respect
next
membran
wash
three
time
pbst
incub
horseradish
hrp
conjug
secondari
antibodi
antirabbithrp
goat
dianova
antimousehrp
goat
dianova
perform
h
room
temperatur
addit
wash
step
membran
incub
houseprepar
enhanc
chemiluminesc
solut
trishcl
ph
luminol
mgml
parahydroxycoumar
acid
h
signal
record
use
chemocam
imag
system
chemostar
profession
softwar
inta
scienc
imag
instrument
gmbh
unwant
cytotox
effect
proteas
inhibitor
treatment
analyz
use
celltiterglo
assay
promega
follow
manufactur
instruct
brief
vero
cell
seed
plate
incub
inhibitor
h
subsequ
assay
substrat
ad
luminesc
quantifi
use
plate
luminomet
hidex
perform
oneand
twoway
analysi
varianc
anova
either
dunnet
comparison
multipl
sampl
singl
refer
sampl
sidak
posttest
multistep
comparison
two
sampl
time
use
graphpad
prism
softwar
packag
graphpad
softwar
p
valu
lower
consid
statist
signific
p
ns
signific
p
p
p
